Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 17/2006

01-12-2006 | Adis Drug Profile

Tacrolimus: In Heart Transplant Recipients

A Viewpoint by Nicholas R. Banner

Author: Nicholas R. Banner

Published in: Drugs | Issue 17/2006

Login to get access

Excerpt

Ciclosporin dramatically improved the results of heart transplantation and made it the standard therapy for severe heart failure. A decade later, tacrolimus (FK506) was introduced into clinical practice. Intriguingly, tacrolimus has a completely different molecular structure and different intracellular binding proteins from ciclosporin, but has the same principal mechanism of action, inhibition of the calcium-dependant phosphatase calcineurin.[1] …
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
1.
Banner NR, Lyster H, Yacoub MH. Clinical immunosuppression using the calcineurin-inhibitors ciclosporin and tacrolimus. In: Pinna LA, Cohen PTW, editors. Inhibitors of protein kinases and protein phosphates. Handbook of Experimental Pharmacology, Vol. 167. New York: Springer, 2005: 321–59CrossRef
2.
Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report, 2005. J Heart Lung Transplant 2005 Aug; 24(8): 945–55PubMedCrossRef
Metadata
Title
Tacrolimus: In Heart Transplant Recipients
A Viewpoint by Nicholas R. Banner
Author
Nicholas R. Banner
Publication date
01-12-2006
Publisher
Springer International Publishing
Published in
Drugs / Issue 17/2006
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200666170-00012

Other articles of this Issue 17/2006

Drugs 17/2006 Go to the issue

Therapy In Practice

Polycythaemia Vera and Essential Thrombocythaemia

Leading Article

Targeted Anti-Cancer Therapies for Renal Cancer

Adis Drug Profile

Sunitinib

Adis Drug Profile

Tacrolimus

Review Article

Current Pharmacological Options for the Management of Primary Hyperparathyroidism

Adis Drug Profile

Tacrolimus: In Heart Transplant Recipients